Fisher Biosciences unit, Cellomics, and Evotec Technologies Sign License Agreement

Companies to collaborate on cell-biology solutions for life-science markets

01-Feb-2006

Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH announced that they have entered into a worldwide, non-exclusive patent license agreement. The agreement will provide Evotec Technologies with Cellomics' core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.

Evotec Technologies and Cellomics are also collaborating to develop and market combined offerings incorporating Cellomics' and Evotec Technologies' products as seamless solutions. This offering will enable cell biologists to obtain the highest quality, most productive results in their drug discovery, systems biology and high content screening efforts.

The two companies will improve the compatibility and integration of their software and assay products, including validation of Cellomics' assay kits by Evotec Technologies. Additional efforts will bring two-way data flow between the complementary platforms and access to enterprise-wide data storage, management, and analysis.

Financial details of the agreement were not disclosed.

https://www.bionity.com/en/news/51970/fisher-biosciences-unit-cellomics-and-evotec-technologies-sign-license-agreement.html